GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Last trade$3.44
Day change-$0.07 (-1.99%)
Day range$3.41 – $3.59
Volume861,573
Market cap$1.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.2B
Price / earnings
73.69×
Price / book
1.85×
Price / sales
1.52×
EV / sales
1.77×
EV / EBITDA
8.48×
Profitability
Earnings per share
$0.05
Return on assets
0.69%
Return on equity
2.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.75×
Current ratio
1.38×
Quick ratio
1.38×
Cash ratio
0.26×
Cash flow
Price / cash flow
5.94×
Price / free cash flow
7.2×
Free cash flow
$166.25M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GDRX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$200.41M
$194.01M
$194.79M
$196.03M
$203.07M
$202.97M
$198.58M
$195.25M
Cost of revenue
$21M
$20.16M
$17.46M
$13.42M
$13.35M
$13.36M
$12.19M
$11.68M
Gross profit
$179.41M
$173.85M
$177.32M
$182.61M
$189.72M
$189.61M
$186.39M
$183.57M
Selling, general and administrative
$106.8M
$107.87M
$102.55M
$115.55M
$113.25M
$114.17M
$117.38M
$115.49M
Research and development
$26.71M
$30.18M
$28.94M
$31.01M
$29.93M
$31.14M
$31.74M
$30.14M
Total operating expenses
$155.78M
$159.84M
$154.64M
$167.99M
$162.91M
$166.23M
$168.21M
$163.16M
Operating income
$23.63M
$14.01M
$22.68M
$14.62M
$26.81M
$23.38M
$18.18M
$20.41M
Interest expense
-$9.81M
-$9.77M
-$10.4M
-$10.83M
-$10.73M
-$10.64M
-$11.36M
-$12.36M
Income before taxes
$15.47M
$5.64M
$14.19M
$6.1M
$19.58M
$16.67M
$11.41M
$8.11M
Income taxes
$6.93M
$4.47M
$8.77M
$4.98M
$6.73M
$5.62M
$4.67M
$4.15M
Net income
$8.54M
$1.17M
$5.43M
$1.12M
$12.84M
$11.05M
$6.74M
$3.97M
Net income attributable to common shareholders
$8.54M
$1.17M
$5.43M
$1.12M
$12.84M
$11.05M
$6.74M
$3.97M
EBITDA
$45.9M
$35.8M
$45.83M
$36.05M
$46.54M
$44.29M
$37.28M
$37.94M
Basic earnings per share
$0.03
$0.00
$0.02
$0.00
$0.04
$0.03
$0.02
$0.01
Diluted earnings per share
$0.02
$0.00
$0.02
$0.00
$0.04
$0.03
$0.02
$0.01
Recent news
Company coverage with links to the original publishers.
Enanta Pharmaceuticals reported a Q4 loss of $0.81 per share, slightly beating the consensus estimate of $0.83 loss, but missed revenue expectations with $12.87 million versus the estimated $13.85 million. The company's stock has declined 30.3% year-to-date, significantly underperforming the S&P 500's 10.5% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting it will perform in line with the market.
Lifeward (LFWD), a maker of wearable robotic exoskeletons, reported a quarterly loss of $1.32 per share, significantly worse than the consensus estimate of $0.53 loss. The company also missed revenue expectations by 35.92%, posting $5.43 million versus the estimated $8.68 million. The stock has declined 17.4% year-to-date and received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Ascend Wellness Holdings reported a Q3 loss of $0.14 per share, missing EPS estimates by 7.69%, though it slightly exceeded revenue expectations at $130.02 million. The stock has underperformed significantly, down 49.5% year-to-date versus the S&P 500's 11.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Icon PLC reported Q3 2026 earnings of $2.66 per share, slightly beating consensus estimates of $2.64, with revenues of $2.02 billion. However, the company has underperformed the S&P 500 year-to-date, gaining only 0.9% versus the market's 12.1% gain. Despite the earnings beat, unfavorable estimate revisions ahead of the report resulted in a Zacks Rank #4 (Sell) rating, suggesting underperformance in the near term. The Medical Services industry ranks in the bottom 39% of Zacks industries.
GoodRx faces revenue stagnation with Q1 2026 sales declining 4.4% year-over-year to $194 million, though its Pharma Direct business showed encouraging 82% growth. Meanwhile, Hims & Hers Health demonstrates strong momentum with 59% year-over-year revenue growth in Q4 2025 and 13% subscriber growth, capitalizing on rising healthcare costs and limited access to primary care physicians.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.